MedGenome, a global leader in multiomics and precision medicine, has announced the appointment of two distinguished executives to lead its US operations.

Felix Olale, M.D., Ph.D., has been named President and Chief Executive Officer (CEO), and Jennifer Rose joins as Executive Vice President and Chief Commercial Officer. Together, these seasoned industry veterans will fuel MedGenome’s expansion in North America, advancing its mission to provide unparalleled insights into disease mechanisms, biomarkers, and personalised medicine through cutting-edge multiomics solutions.

Dr Olale, a global leader in genomics and healthcare, most recently served as Global Co-Lead of Healthcare Investments at LeapFrog Investments, a pioneer in impact investing and a global expert in scaling purpose-driven businesses. His leadership at MedGenome will accelerate the company’s transformation into the preferred partner for academic institutions, biopharma, and biotech companies seeking advanced multiomic and genomic technologies to tackle the most challenging scientific questions, helping them develop medicines for patients in areas of unmet need.

Dr Olale’s appointment as CEO follows his previous role as Chairman of MedGenome’s Board of Directors, where he played a pivotal role in shaping the company’s strategy. He steps into his leadership role as Dr Amit Kakar, Managing Partner and Head of Novo Holdings Asia, takes over as Chairman.

Jennifer Rose, on the other hand, brings extensive expertise in life sciences, having previously served as Regional Vice President of Business Development at Precision for Medicine, a global clinical research organisation. She has held senior leadership roles at NeoGenomics Laboratories, GE Healthcare, PerkinElmer, and Thomson Reuters.